Pharma News, 2024

In a worldwide first-of-its-kind study published in the journal Nature Communications this week, a team of scientists from Children's Medical Research Institute (CMRI)

Megablockbuster Keytruda was last year's best-selling drug with more than $25 billion in sales. (Merck & Co.)

After a few holdups, Swiss skincare company Galderma is finally going public in a highly anticipated market debut that could make for one of Europe’s largest listings this year.

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk (NOVOb.CO), opens new tab, plans to open an office in India this year to tap innovation and a growing healthcare...

Today, the U.S. Food and Drug Administration (FDA) announced it is requesting $7.2 billion as part of the President’s fiscal year (FY) 2025 proposed budget.

The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis...

Valneva has announced that its single-dose vaccine, Ixchiq, has been recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ...

The popular weight-loss drug, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who ...

Eli Lilly said that the Food and Drug Administration has pushed back its approval decision deadline for the drugmaker’s experimental Alzheimer’s treatment donanemab in a surprise move.

Integrating Ambrx's ADC technology into J&J's portfolio will aid in advancing the development of targeted oncology therapies. Johnson & Johnson (J&J) has concluded the acquisition of c...

The company says it will pause promotion of the drug, Relyvrio (sodium phenylbutyrate plus taurursodiol), and may pull it from the market in the coming weeks.

The investment will also help to enhance public health protection and pandemic preparedness in the UK.